R&D Partner Content 2nd Gene Therapy Potency Assay Summit Returns to Boston! Effectively Measure Potency to Ensure Reproducible Results For Your Gene Therapy
R&D Partner Content 3rd Process Development for Cell Therapies Summit In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.
R&D Partner Content GLP-1-Based Therapeutics Summit Advancing Specialized, Durable, & Efficacious GLP-1s & Investigating Commercial Opportunity to Crystallize Pipeline Strategy & Indication Expansion
R&D Partner Content Cell & Gene Therapy Pricing & Reimbursement Summit Unlocking Patient Access to Affordable Advanced Therapies
R&D Partner Content 6th Allogeneic Cell Therapies Summit Driving Potency, Efficacy & Durability of Universal Cell Therapies
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.